Results 91 to 100 of about 10,523 (190)

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Journal of Lipid Research, 2010
Over the past several years, proprotein convertase subtilisin kexin type 9 (PCSK9) has gained significant attention as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Jason S. Troutt, William E. Alborn, Guoqing Cao, Robert J. Konrad   +3 more
doaj   +1 more source

Epigenetic Regulation in Cardiovascular Diseases: Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 6, June 2026.
Environmental and lifestyle exposures reshape the cardiovascular epigenome through coordinated regulation of DNA methylation, histone modifications, noncoding RNAs, and RNA methylation (m6A). These multilayered mechanisms drive enhancer‐centered regulatory network remodeling and epigenomic plasticity in cardiovascular diseases, highlighting emerging ...
Wangzheqi Zhang, Chenyang Mu, Rui Zhao, Runwei Ma, Xuehai Liu, Haoling Zhang, Zengwu Wang, Jing‐jing Zhang   +7 more
wiley   +1 more source

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

JACC: Basic to Translational Science
Summary: We investigated the potential of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies to restore macrophage cholesterol efflux in subjects with heterozygous familial hypercholesterolemia (FH) and to enhance the macrophage-specific ...
Carla Borràs, MSc, Marina Canyelles, PhD, Josefa Girona, PhD, Daiana Ibarretxe, MD, PhD, David Santos, BS, Giovanna Revilla, PhD, Vicenta Llorente-Cortes, PhD, Noemí Rotllan, PhD, Petri T. Kovanen, MD, PhD, Matti Jauhiainen, PhD, Miriam Lee-Rueckert, PhD, Luis Masana, MD, PhD, Francisco Arrieta, MD, PhD, Javier Martínez-Botas, PhD, Diego Gómez-Coronado, PhD, Josep Ribalta, PhD, Mireia Tondo, PhD, Francisco Blanco-Vaca, MD, PhD, Joan Carles Escolà-Gil, PhD   +18 more
doaj   +1 more source

Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 6, June 2026.
FBP1 loss drives immune evasion and therapy resistance by enhancing glycolysis, STAT3 activation, and PD‐L1 expression, leading to T cell exhaustion and NK cell inhibition. FBP1 restoration, via LNP‐mRNA or epigenetic modulation, reverses these immunosuppressive effects, reactivates cytotoxic T cells, promotes M1 macrophage polarization, and enhances ...
Chunwei Li, Ziqiang Liu, Dezheng Kong, Zhengze Li, Yiming Yan, Yanyu Dong, Lili Zhu, JiaNing Cao, Zhirui Fan, Gautam Sethi, Lifeng Li   +10 more
wiley   +1 more source

Single‐nucleotide polymorphisms in coronary artery disease: Biological complexity, risk architecture, and implications for precision prevention

Precision Medical Sciences, Volume 15, Issue 2, Page 91-101, June 2026.
This graphical summary highlights the clinical application of single‐nucleotide polymorphisms‐based risk stratification in coronary artery disease. By integrating polygenic risk with clinical assessment, imaging, and preventive strategies, genetic information enables earlier risk identification, optimized screening, and personalized lifestyle and ...
Li Dai, Mosi Chen, Jun Hu, Lei Huang, Ye Yang, Chang Chen, Ying Zhuang, Yan Pan, Bingjun Qian   +8 more
wiley   +1 more source

The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Statins, widely prescribed for cardiovascular prevention, have emerged as potential disease‐modifying agents in neurodegenerative disorders due to their pleiotropic effects on cholesterol metabolism, neuroinflammation, oxidative stress, and protein aggregation.
Luigi Maria Chiatto, Lucia Buccarello, Giuseppe Carota, Rocco Salvatore Calabrò, Carmela Rifici, Emanuela Esposito, Alessio Ardizzone, Giuseppe Caruso   +7 more
wiley   +1 more source

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik, Hua-Poo Su, Yacob Gomez Llorente, Rachel L. Palte, Daniel J. Klein, Robert P. Hayes, Sadie P. Antine, Guilermo A. Asmar-Rovira, Nicole Bertoletti, Noel J. Byrne, Brittany L. Carroll, Ciro D. Cordeiro, Kaylynn Curfman, James Dutko, Michael J. Eddins, Thierry Fischmann, Barani Govindarajan, Corey W. Hecksel, Thu Ho, Kaspar Hollenstein, Mee Ra Hong, Alan Hruza, Andrii Ishchenko, Maru Jaime-Garza, Matt J. Jaremko, Hayley L. Knox, James Kostas, Harini Krishnamurthy, Ioannis Manolaridis, Cameron L. Noland, Andrea T. Partridge, Sangita B. Patel, Paul Reichert, John C. Reid, Catarina Felisberto-Rodrigues, Chitra A. Shintre, Jennifer M. Shipman, Elakkiya Tamilselvan, Morgan E. Walker, Susanne N. Walker, Renjing Wang, Katharine M. Wright, Tien-Jui Yen, Byung-Kuk Yoo, Sandra B. Gabelli   +44 more
wiley   +1 more source

PCSK9 Promotes Platelet Activation and NET Formation, Aggravating Pulmonary Microthrombosis in Sepsis-Induced Lung Injury

Biomedicines
Background: Sepsis-induced lung injury is a major clinical challenge, frequently complicated by pulmonary microthrombosis, which exacerbates disease severity and worsens prognosis. Recent studies suggest that proprotein convertase subtilisin/kexin type 9
Xin Lv, Wanxia Xiong, Linghui Jiang
doaj   +1 more source

PCSK9 Inhibitors

Journal of the American College of Cardiology, 2017
Mark A. Hlatky, Dhruv S. Kazi
openaire   +2 more sources

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice

Frontiers in Pharmacology
InstructionAccumulating evidence has shown that proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with inflammation in the vascular system. However, the roles of PCSK9 in hepatic inflammation remain unclear.
Xue-Ying Zhang, Qing-Qing Lu, Yan-Jie Li, Shan-Rui Shi, Chao-Nan Ma, Miao Miao, Shou-Dong Guo   +6 more
doaj   +1 more source